Last reviewed · How we verify
Investigational varicella vaccine_Lot 2
Investigational varicella vaccine_Lot 2 is a Live attenuated vaccine Biologic drug developed by GlaxoSmithKline. It is currently in Phase 3 development for Prevention of varicella (chickenpox) in pediatric and adult populations.
This vaccine stimulates the immune system to recognize and prevent varicella-zoster virus infection by inducing protective antibodies and cell-mediated immunity.
This vaccine stimulates the immune system to recognize and prevent varicella-zoster virus infection by inducing protective antibodies and cell-mediated immunity. Used for Prevention of varicella (chickenpox) in pediatric and adult populations.
At a glance
| Generic name | Investigational varicella vaccine_Lot 2 |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Live attenuated vaccine |
| Target | Varicella-zoster virus (VZV) glycoproteins |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Varicella vaccines work by presenting viral antigens (typically attenuated or inactivated virus components) to the immune system, triggering both humoral and cellular immune responses. This priming allows the body to rapidly recognize and neutralize varicella-zoster virus upon natural exposure, preventing chickenpox infection or reducing disease severity.
Approved indications
- Prevention of varicella (chickenpox) in pediatric and adult populations
Common side effects
- Injection site reactions (erythema, swelling, pain)
- Fever
- Rash
- Myalgia or arthralgia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Investigational varicella vaccine_Lot 2 CI brief — competitive landscape report
- Investigational varicella vaccine_Lot 2 updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about Investigational varicella vaccine_Lot 2
What is Investigational varicella vaccine_Lot 2?
How does Investigational varicella vaccine_Lot 2 work?
What is Investigational varicella vaccine_Lot 2 used for?
Who makes Investigational varicella vaccine_Lot 2?
What drug class is Investigational varicella vaccine_Lot 2 in?
What development phase is Investigational varicella vaccine_Lot 2 in?
What are the side effects of Investigational varicella vaccine_Lot 2?
What does Investigational varicella vaccine_Lot 2 target?
Related
- Drug class: All Live attenuated vaccine drugs
- Target: All drugs targeting Varicella-zoster virus (VZV) glycoproteins
- Manufacturer: GlaxoSmithKline — full pipeline
- Therapeutic area: All drugs in Immunology / Infectious Disease
- Indication: Drugs for Prevention of varicella (chickenpox) in pediatric and adult populations
- Compare: Investigational varicella vaccine_Lot 2 vs similar drugs
- Pricing: Investigational varicella vaccine_Lot 2 cost, discount & access